Cargando…

Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma

INTRODUCTION: Current treatments for patients with previously treated advanced hepatocellular carcinoma (HCC) provide modest survival benefits. We evaluated the safety and antitumor activity of serplulimab, an anti-PD-1 antibody, plus the bevacizumab biosimilar HLX04 in this patient population. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Zhenggang, Shao, Guoliang, Shen, Jie, Zhang, Li, Zhu, Xu, Fang, Weijia, Sun, Guoping, Bai, Yuxian, Wu, Jianbing, Liu, Lianxin, Yuan, Yuan, Zhang, Jingdong, Li, Zhen, Zhang, Ling, Yin, Tao, Wu, Jincai, Hou, Xiaoli, Wang, Qingyu, Zhu, Jun, Fan, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267516/ https://www.ncbi.nlm.nih.gov/pubmed/37325495 http://dx.doi.org/10.1159/000526638

Ejemplares similares

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study
por: Qin, Shukui, et al.
Publicado: (2021)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers
por: Zhu, Xiaoxue, et al.
Publicado: (2021)

Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
por: Xu, Yanpeng, et al.
Publicado: (2019)

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
por: Cai, Lin, et al.
Publicado: (2021)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2020)

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
por: Song, Yan, et al.
Publicado: (2023)

HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
por: Yang, Jingjing, et al.
Publicado: (2022)

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study
por: An, Jusheng, et al.
Publicado: (2023)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
por: Zhang, Hong, et al.
Publicado: (2021)

HLX in AML: novel prognostic and therapeutic target
por: Pandolfi, Ashley, et al.
Publicado: (2012)

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
por: Qin, Shukui, et al.
Publicado: (2022)

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2021)

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2023)

HLX affects cell cycle and proliferation in AML cells via the JAK/STAT signaling pathway
por: Zhu, Xia-Yin, et al.
Publicado: (2020)

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
por: Qin, Shukui, et al.
Publicado: (2022)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study
por: Zeng, Xiaofeng, et al.
Publicado: (2022)

Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin(®) with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology
por: Xie, Liqi, et al.
Publicado: (2020)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma
por: Nagel, Stefan, et al.
Publicado: (2018)

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
por: Seo, Neungseon, et al.
Publicado: (2018)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

TBX21 and HLX1 Polymorphisms Influence Cytokine Secretion at Birth
por: Casaca, Vera Isabel, et al.
Publicado: (2012)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
por: Cao, Di, et al.
Publicado: (2023)

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
por: Monk, Bradley J., et al.
Publicado: (2017)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020)

The Hlx homeobox transcription factor is required early in enteric nervous system development
por: Bates, Michael D, et al.
Publicado: (2006)

Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL
por: Nagel, Stefan, et al.
Publicado: (2019)

Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China
por: Long, Yunchun, et al.
Publicado: (2023)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
por: Huang, Kai, et al.
Publicado: (2021)

Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
por: Lashay, Alireza, et al.
Publicado: (2020)

Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series
por: Mirshahi, Ahmad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ss31clli01s0mcsrfuifee0h56